YOLT 203
Alternative Names: YOLT-203Latest Information Update: 26 Aug 2026
At a glance
- Originator YolTech Therapeutics
- Class Gene therapies; Uricosurics
- Mechanism of Action Gene expression modulators; Glycolate oxidase expression inhibitors
-
Orphan Drug Status
Yes - Primary hyperoxaluria type 1
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Primary hyperoxaluria type 1
- Preclinical Hyperuricaemia
Most Recent Events
- 20 Aug 2026 Phase-I clinical trials in Primary hyperoxaluria type 1 (In adolescents, In children) in China (IV) (NCT07776626)
- 12 Aug 2026 Phase-II clinical trials in Primary hyperoxaluria type 1 (In adults, In adolescents, In children, In the elderly) in USA (IV) (NCT07587021)
- 14 May 2026 YolTech Therapeutics plans a phase II trial for Primary-hyperoxaluria in June 2026 (IV) (NCT07587021)